Macquarie Healthcare isn’t a compelling source of exposure to its target sector.
Nomura Healthcare Fund Class I DLHIX
- NAV / 1-Day Return 26.03 / −0.65 %
- Total Assets 699.3M
-
Adj. Expense Ratio
0.960%
- Expense Ratio 0.960%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Health
- Investment Style Mid Value
- Min. Initial Investment 0
- Status Open
- TTM Yield 2.58%
- Turnover 5%
USD | NAV as of Jun 06, 2026 | 1-Day Return as of Jun 06, 2026, 2:17 AM GMT+0
Morningstar’s Analysis DLHIX
Will DLHIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the DLHIX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of DLHIX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 39.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
UCB SA | 5.13 | 35M | Healthcare |
Regeneron Pharmaceuticals Inc | 4.81 | 33M | Healthcare |
Pfizer Inc | 4.43 | 31M | Healthcare |
Gilead Sciences Inc | 3.98 | 27M | Healthcare |
AbbVie Inc | 3.82 | 26M | Healthcare |
UnitedHealth Group Inc | 3.75 | 26M | Healthcare |
AstraZeneca PLC | 3.60 | 25M | Healthcare |
Eli Lilly and Co | 3.52 | 24M | Healthcare |
Chugai Pharmaceutical Co Ltd | 3.47 | 24M | Healthcare |
Elevance Health Inc | 3.43 | 24M | Healthcare |
United States